Top Wall Street Forecasters Revamp Waters Expectations Ahead Of Q2 Earnings

Waters Corporation (WAT) is scheduled to report Q2 earnings on August 4, with analysts forecasting EPS of $2.94 and revenue of $748.51 million, both increases year-over-year. This comes after the company's July 14 agreement to combine with Becton, Dickinson’s Biosciences & Diagnostic Solutions business. WAT shares closed up 0.5% at $290.31, against a backdrop of mixed recent analyst ratings including a downgrade from Wells Fargo.

Analysis

Waters Corporation (WAT) is approaching its second-quarter earnings release with consensus expectations for solid year-over-year growth, forecasting EPS of $2.94 from $2.63 and revenue of $748.51 million from $708.53 million. This anticipated financial performance follows a significant strategic development: the July 14 agreement to combine with Becton, Dickinson’s Biosciences & Diagnostic Solutions business. Despite these positive catalysts, recent sentiment from high-accuracy analysts is notably cautious. The most recent action was a material downgrade from Wells Fargo on July 15, moving the stock to Equal-Weight from Overweight and cutting the price target to $330 from $420. This contrasts with the broader trend of Neutral or Hold ratings from other analysts at B of A Securities, UBS, and JP Morgan, who have issued mixed price target revisions. The stock's recent modest gain to $290.31 positions it well below all cited analyst price targets, indicating a potential valuation disconnect that the market will scrutinize in the upcoming earnings call and management outlook.

Key Decisions for Investors

• Investors should closely monitor the upcoming earnings call not just for the Q2 results, but more critically for management's guidance on the integration of the Becton, Dickinson business and its expected impact on future growth and synergies.
• The divergence between positive consensus earnings growth and the recent, significant downgrade from a high-accuracy Wells Fargo analyst warrants caution; consider the potential risks that may have prompted the move to an Equal-Weight rating.
• Given the stock price of $290.31 is substantially below even the lowest recent analyst price target of $330, investors may see a favorable risk-reward setup, but the prevailing Neutral ratings suggest holding existing positions rather than initiating aggressive new ones ahead of the report.